Change of the number of shares and votes in Diamyd Medical AB

As of June 23, 2015, the share capital in Diamyd Medical AB (publ) is SEK 2,243,414.8. The total number of votes is 3,074,668 and the total number of shares is 22,119,422, divided among 958,584 shares of series A (1 vote) and 21,160,838 shares of series B (1/10 vote).

The change is, as previously announced on September 16, 2014, due to a direct placement of 300,000 new series B shares to Protein Sciences Corporation, Inc., due to a signed agreement. 100,000 series B shares have, as previously announced on December 2, 2014, already been issued due to the same agreement. The Board of Diamyd Medical decided on the new issue based on the authorization given by the Annual General Meeting on November 27, 2014.

About Diamyd Medical
Diamyd Medical is dedicated to working toward a cure for type 1 diabetes and LADA. The Company’s projects include development of combination regimens with the GAD-based diabetes vaccine Diamyd® for arresting the destruction of insulin-producing beta cells. The Company exclusively licenses UCLA-rights to GAD65, the active ingredient in the vaccine, for which the last patent expires in 2032. Additionally, the Company exclusively licenses UCLA patents for using GABA for the treatment of diabetes and other inflammation-related conditions.

Diamyd Medical is one of the major shareholders in the stem cell company Cellaviva AB, which is establishing a Swedish commercial bank for private family saving of stem cells in umbilical cord blood and other sources of stem cells. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example, to restore beta cell mass in diabetes patients where autoimmunity has been arrested.

Remium Nordic AB is the Company’s Certified Adviser.

For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.

Tags:

About Us

Diamyd Medical is a Swedish diabetes company dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell- and medical technology.

Subscribe

Documents & Links